Sagimet Biosciences (SGMT) Retained Earnings (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Retained Earnings of $459.4 million for Q1 2026, up 1.57% year-over-year from $452.4 million in Q1 2025, and up 382771.67% quarter-over-quarter from $120000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Retained Earnings (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Retained Earnings history runs 5 years deep, the most recent figure standing at $459.4 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 1.57% year-over-year to $459.4 million; the TTM figure through Mar 2026 stood at $459.4 million (up 1.57% YoY), while the FY2025 annual figure was $120000.0, down 47.83% from the prior year.
- Retained Earnings for Q1 2026 stood at $459.4 million, up from $120000.0 in the prior quarter.
- The five-year high for Retained Earnings was $459.4 million in Q1 2026, with the low at -$279.1 million in Q3 2024.
- The 5-year median for Retained Earnings is $117000.0 (2025), against an average of -$23.6 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings plunged 818.24% in 2024, then soared 276.43% in 2025.
- Sagimet Biosciences' Retained Earnings stood at $35.0 million in 2022, then plunged by 813.53% to -$249.7 million in 2023, then soared by 100.09% to $230000.0 in 2024, then slumped by 47.83% to $120000.0 in 2025, then surged by 382771.67% to $459.4 million in 2026.
- Business Quant data shows SGMT's Retained Earnings at $459.4 million in Q1 2026, $120000.0 in Q4 2025, and $117000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 627.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 627.18 Mn |
| Mar 31, 2026 | 459.45 Mn |
| Dec 31, 2025 | 120,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Mar 31, 2025 | 452.36 Mn |
| Dec 31, 2024 | 230,000.00 |
| Sep 30, 2024 | -279.11 Mn |
| Jun 30, 2024 | -264.49 Mn |
| Mar 31, 2024 | -256.40 Mn |
| Dec 31, 2023 | -249.74 Mn |
| Sep 30, 2023 | -241.59 Mn |
| Jun 30, 2023 | 36.83 Mn |
| Dec 31, 2022 | 35.00 Mn |